IDBS has announced that pre-clinical contract research organisation (CRO) Pharmalegacy Laboratories has selected the E-workbook Suite to increase its research and development productivity.
Providing speciality pharmacology services in oncology, bone, inflammation and immune diseases, Pharmalegacy sought a 21 CFR Part 11 compliant solution for the capture of DMPK and pharmacology data to deliver improved customer service to clients.
Biobook, the biology extension of the E-workbook Suite, will be used by Pharmalegacy scientists in Shanghai as the company continues to expand and grow its customer base.
Biobook will enable the company to increase client productivity and the pace of new drug development by providing management and analysis of complex research data.
Tom Tillotson, vice president corporate planning at Pharmalegacy, said: 'We have a vision to collaborate with our clients to accelerate their research missions to develop new therapies.
'The E-workbook Suite provides us with the highest level of IP protection and regulatory compliance and will enable us to offer improved discovery, development and management capabilities to the marketplace.
'The benefits will be particularly great where clients are utilising the Biobook technology.
'Biobook will provide us with an excellent opportunity to develop long-term partnerships with biotechnology and pharmaceutical clients.' 'Biobook provides focused pre-clinical data management extension to ensure maximum productivity and will help Pharmalegacy to deliver competitive advantage to clients in the pharmaceutical and biotechnology industries,' said Neil Kipling, founder and chief executive officer of IDBS.
